Document:

CONFIDENTIAL TREATMENT REQUESTED                                   EXHIBIT 10.10

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24(B)(2) OF THE SECURITIES AND
EXCHANGE ACT OF 1934. CONFIDENTIAL TREATMENT REQUESTED IS REQUESTED AND IS NOTED
WITH "[CONFIDENTIAL TREATMENT REQUESTED]." AN UNREDACTED VERSION OF THIS
DOCUMENT HAS BEEN PREVIOUSLY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

                        PHENYLBUTYRATE CO-DEVELOPMENT AND
                              SUBLICENSE AGREEMENT
                                  BY AND AMONG
                      BRIDGE THERAPEUTIC PRODUCTS, INC AND
                         BRIDGE ONCOLOGY PRODUCTS, INC.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED
Strictly Confidential

                              SUBLICENSE AGREEMENT

         THIS AGREEMENT (the "Agreement"), is made and effective as of February
16, 2005 (the "Effective Date"), by and between Bridge Therapeutic Products Inc.
("BTP") and Bridge Oncology Products Inc. ("BOP" and, together with BTP, the
"Parties").

                                    RECITALS:

         WHEREAS BTP, Inc. ("BTP") has worldwide rights to intellectual
property, commercialization rights and know how pertaining to phenylbutyrate
("PB" or the "PB Technology"), and

         WHEREAS Bridge Oncology Inc. ("BOP") wishes to enter into an exclusive
sublicense to all of BTP's PB Technology in the Territory (defined as worldwide
with the exception of the United States of America and Canada), including,
without limitation, any and all patents, patent applications, continuations,
continuations-in-part, inventions, improvements, know how, trademarks, trade
secrets, and any and all other intellectual property or proprietary information
related thereto, in each case, together with any and all commercialization
rights pertaining to the PB technology (collectively, the "Sublicensed
Technology").

         NOW, THEREFORE, in consideration of the mutual premises, covenants and
agreements set forth in this Sublicense Agreement, and other good and valuable
consideration the receipt and sufficiency of which is hereby acknowledged, BTP
and BOP hereby agree as follows:

1.       Grant of Sublicense

         1.1      The intention and purpose of the Sublicense Agreement is to
                  continue to promote the on-going development programs already
                  instituted by BTP and outside clinical investigators for PB,
                  to maximize the potential therapeutic benefit of PB for the
                  treatment of certain cancers, autoimmune diseases and other
                  clinical indications, and to expedite a global strategy for
                  the development, regulatory approval and commercial
                  development of PB.

         1.2      BTP hereby grants to BOP an exclusive sub-license to all of
                  BTP's intellectual property rights, including without
                  limitation, any and all patents, patent applications,
                  continuations, continuations-in-part, inventions,
                  improvements, trademarks, trade secrets, and any and all other
                  intellectual property or proprietary information related
                  thereto, in each case, together with any and all
                  commercialization rights and all know how to PB (collectively,
                  the "Sublicense") in the Territory (defined as worldwide with
                  the exception of the United States of America and Canada). For
                  purposes of this Sublicense Agreement, the parties hereto
                  acknowledge and agree that the Sublicense shall include,
                  without limitation, all rights, title and interest to the
                  Public Health Service Patent License Agreement, dated May 25,
                  1995, between the Public Health Service and the National
                  Institute of Health and BTP, in the form attached as Exhibit 1
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                  hereto (the "PHSP License Agreement"), together with all
                  rights, title and interests conveyed thereunder.

2.       Consideration

         2.1      In consideration of the Sublicensed Technology, BOP agrees to
                  pay BTP [CONFIDENTIAL TREATMENT REQUESTED] as soon as
                  commercially reasonable after the Effective Date.

         2.2      BOP will pay royalties to BTP on all direct sales of PB or any
                  product incorporating the PB Technology within the Territory
                  of [CONFIDENTIAL TREATMENT REQUESTED]. In any country with the
                  Territory where PB or any product incorporating the PB
                  Technology is sold by a third party, such as distributor,
                  wholesaler or marketing company, any payments made by their
                  third party as part of the acquisition of rights to sell or
                  distribute PB or any product incorporating the PB Technology
                  shall be shared equally between BOP and BTP.

         2.3      BOP agrees to pay all costs and expenses of prosecuting,
                  filing and maintaining Patents and defending revocation
                  proceedings on patent and patent applications on PB in all
                  other countries within the Territory (which specifically
                  excludes the United States of America and Canada).

3.       Co-Development Plan

         3.1      The parties to this Agreement hereby agree to cooperate in the
                  development and commercialization of PB. BTP will be
                  responsible for conducting all clinical trials and the filing
                  and prosecution of all applications with applicable USA and
                  Canadian regulatory authorities, and all regulatory filings in
                  the USA and Canada will be in the name of BTP. BOP will be
                  responsible for conducting all clinical trials and the filing
                  and prosecution of all applications with applicable regulatory
                  authorities other than in the USA and Canada and all such
                  filings shall be in the name of BOP.

         3.2      The parties will promptly share all information generated
                  under this co-development program pursuant to confidentiality
                  including, without limitation, all information with respect to
                  market analysis, competitor position, pre-clinical and
                  clinical trials, the filing of any applications with the US
                  Food and Drug Administration or similar Canadian authority and
                  the manufacture and testing of different formulations and
                  preparations of PB or any product incorporating the PB
                  Technology.

         3.3      BTP shall pay all costs and expenses of any work deemed
                  necessary for the development of PB in the USA and Canada. BOP
                  shall pay all costs and expenses of any work deemed necessary
                  for the development of PB in any other countries within the
                  Territory (other than USA or Canada).

                                       2
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

4.       Representations and Warranties

         4.1      The parties agree that this Agreement shall constitute a
                  binding and enforceable agreement between the parties. In this
                  regard, the parties agree to use commercially reasonable
                  efforts to work together in good faith to obtain all necessary
                  consents and approvals required from the National Institute of
                  Health's Public Health Service and any other third party or
                  governmental authority reasonably required to provide a
                  consent, if any, as soon as reasonably practicable after the
                  date hereof.

         4.2      BTP hereby represents, warrants and covenants to BOP that BTP
                  has full right, power and authority to enter into this
                  Agreement.

         4.3      BOP represents that it has full power, authority to enter into
                  this Agreement.

         4.4      BTP is unaware of any claims asserted against BTP by any third
                  parties with respect to patent infringement or any other type
                  of liability relevant to licensing or sub-licensing of the
                  Sublicensed Technology.

         4.5      The execution of this Agreement by BTP shall not contravene
                  any provision of law or any contract to which BTP is a party.
                  The execution of this Agreement by BOP shall not contravene
                  any provision of law or any contract to which BOP is a party.

5.       Other Considerations; General Provisions

         5.1      Confidentiality: In fulfilling their obligations under this
                  Sublicense Agreement, it may be desirable or necessary for BTP
                  and BOP to disclose to one another certain confidential
                  information. In the event of receipt of such confidential
                  information, the receiving party agrees to preserve such
                  information as confidential and not disclose it to third
                  parties or to use it except where legally or commercially
                  required to do so, in the reasonable opinion of counsel to the
                  disclosing party.

         5.2      Governing law: This Agreement shall be construed and enforced
                  in accordance with the substantive laws of the State of New
                  York, without regard to the principles thereof regarding the
                  choice of law.

         5.3      Severability: If any provision(s) of this Sublicense Agreement
                  shall be determined to be invalid or unenforceable, the
                  validity and effect of the other provisions of this Sublicense
                  Agreement shall not be affected thereby.

         5.4      Waiver: The waiver by either party or the failure by either
                  party to claim a breach of any provision of this Sublicense
                  Agreement shall not be deemed to constitute a waiver or
                  estoppel with respect to any subsequent breach or with respect
                  to any provision thereof.

         5.5      Successors and Assigns: This Sublicense Agreement shall be
                  binding upon and shall inure to the benefit of the Parties and
                  their respective successors and assigns.

                                       3
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

         5.6      Further Assurances: Each Party covenants and agrees to use
                  commercially reasonable efforts to take, or cause to be taken,
                  all actions and to do, or cause to be done, all things
                  reasonably required, necessary or appropriate, in good faith,
                  to make effective the transactions contemplated by this
                  Sublicense Agreement, including, without limitation, the
                  conveyance of the Sublicensed Technology.

         5.7      Counterparts: This Sublicense Agreement may be executed in any
                  number of counterparts, each of which shall be deemed an
                  original but all of which together shall constitute a single
                  instrument.

         IN WITNESS WHEREOF, the parties have executed this Agreement by their
duly authorized representatives as of February 16, 2005.

Bridge Therapeutic Products Inc.          Bridge Oncology Products Inc.

Signature: /s/ JEFFREY B. DAVIS           Signature: /s/ STEVEN H. ROUHANDEH
          ----------------------------              ----------------------------

Name:       Jeffrey B. Davis              Name:       Steven H. Rouhandeh
     ---------------------------------         ---------------------------------

Position:   Chairman                      Position:   Chairman
         -----------------------------             -----------------------------

Date:       2/16/05                       Date:       2/16/05
     ---------------------------------         ---------------------------------

                                       4CONFIDENTIAL TREATMENT REQUESTED                                   EXHIBIT 10.11

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24(b)(2) OF THE SECURITIES AND
EXCHANGE ACT OF 1934. CONFIDENTIAL TREATMENT REQUESTED IS REQUESTED AND IS NOTED
WITH "[CONFIDENTIAL TREATMENT REQUESTED]." AN UNREDACTED VERSION OF THIS
DOCUMENT HAS BEEN PREVIOUSLY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

                               PATENT AND KNOW-HOW
                              EXCLUSIVE SUBLICENSE
                                    AGREEMENT
                                  BY AND AMONG
                                 IMMUNODEX, INC.
                                       AND
                                 SOMANTA LIMITED

                                       1
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

               Patent and Know-how Exclusive Sublicense Agreement

THIS PATENT AND KNOW-HOW EXCLUSIVE SUBLICENSE AGREEMENT (the "Agreement") dated
August 18, 2005 is between:

(1)     IMMUNODEX ("Immunodex") a United States company incorporated under the
        laws of the State of California whose principal address is 1230 H
        Street, Eureka, CA, United States Of America; and

(2)     SOMANTA LIMITED ("Somanta") a company incorporated in England and Wales
        whose principal place of business is at 80 Harley Street, London, W1G
        7HB, United Kingdom, and formerly known as Somantis Limited.

RECITALS:

A.      Immunodex has an exclusive license and rights to sub-license the BrE-3
        Patents and the Mc-3 Patents and related know-how from Cancer Research
        Institute of Contra Costa ("CRICC").

B.      Immunodex is willing to grant to Somanta and Somanta is willing to
        accept, an exclusive sublicense, with the right to further sublicense,
        to the BrE-3 Patents and Mc-3 Patents and related know-how for the
        treatment of human cancer worldwide, in accordance with the provisions
        of this Agreement.

C.      Immunodex and Somanta were previously parties to that certain Patent and
        Know-how License Option Agreement dated March 1, 2002 as amended by that
        certain Amendment No. 1 to Patent and Know-how License Option Agreement
        dated January 2, 2003, Amendment No. 2 to Patent and Know-how License
        Option Agreement dated October 14, 2003 and Amendment No. 3 to Patent
        and Know-how License Option Agreement dated October 29, 2004
        (collectively, referred to herein as the "Option Agreement"), such
        Option Agreement related to the subject matter hereof.

D.      Immunodex and Somanta now desire to terminate the Option Agreement in
        its entirety and to supersede the Option Agreement with this Agreement.

IT IS AGREED as follows:

1.      Definitions

In this Agreement, the following words shall have the following meanings:

Affiliate               In relation to a Party, means a person, corporation
                        partnership, or other entity that controls, is
                        controlled by, or is under common control with that
                        Party. For the purposes of this Section, the word

                                       2
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                        "control" (including, with correlative meaning, the
                        terms "controlled by" or "under the common control
                        with") means the actual power, either directly or
                        indirectly through one or more intermediaries, to direct
                        the management and policies of such entity, either by
                        the ownership of at least fifty percent (50%) of the
                        voting stock of such entity or by contract law or
                        otherwise.

BrE-3                   The antibody known as BrE-3 and all forms and
                        derivatives thereof, including, without limitation,
                        humanized and non-humanised forms, its native form and
                        radio-labelled forms for a pharmaceutical formulation
                        for human use, and all fragments thereof.

BrE-3 Patents           BrE-3 Patents are the Patents described in Schedule 1
                        Part A; all substitutions, extensions, registrations,
                        confirmations, reissues, reexaminations, renewals and
                        like filings of any of the foregoing patents; all
                        non-United States Patents that are counterparts to any
                        of the foregoing patents and/or any patent applications
                        that gave rise to any of the foregoing patents, together
                        with all Patents claiming priority thereto and issuing
                        therefrom (but excluding the claims of any such Patents
                        to the extent directed to any new matter that may be
                        claimed in any continuation-in-part or similar
                        application outside the United States).

Chelate License         The sub-license agreement between Cancer Research
                        Institute of Contra Costa and Coulter Corporation dated
                        January 18, 1994.

Commencement Date       The date of this Agreement as set forth in the first
                        paragraph hereof.

Control                 Owned or in-licensed with the right to grant a license
                        or sublicense (as applicable) as set forth herein
                        without violating the terms of any agreement or other
                        arrangement with any third party, or the license
                        agreement between Immunodex and CRICC dated April 19,
                        2002.

CRICC                   The meaning given in Recital A.

Escrow Amount 1         The amount of money to be deposited upon the signing of
                        this Agreement in accordance with Section 4.1(c), and
                        distributed in accordance with 2.3.1 (a).

Escrow Amount 2         The amount of money to be deposited at the time and as
                        set forth in Section 4.1(d), and destributed in
                        accordance with 2.3.1(b).

Field                   The diagnostic imaging and treatment of human cancer.

                                       3
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

First Commercial Sale   With respect to any Royalty-bearing Product, the first
                        sale for end use or consumption of such Royalty-bearing
                        Product in a country after the governing health
                        regulatory authority of such country has granted
                        regulatory approval of such Royalty-bearing Product (in
                        countries where regulatory approval is required).

Funding                 The date on which Somanta or its successor, assignee,
                        Affiliate and/or Bridge Oncology Products, Inc. or its
                        successor, assignee or Affiliate closes an equity
                        transaction with gross proceeds to Somanta or such
                        entity of no less than US$10 million.

Know-how                All technical information or confidential information or
                        materials in the Field to the extent Controlled by
                        Immunodex as of the Effective Date relating to the
                        inventions claimed in the BrE-3 Patents and/or the Mc-3
                        Patents or relating to the antibodies BrE-3 or Mc-3,
                        including, but not limited to all pharmaceutical
                        formulations, chemistry, manufacturing and purification
                        and labelling, pre-clinical and clinical data, results,
                        applications for regulatory approvals and other
                        information.

Licensed Patents        The BrE-3 Patents and the Mc-3 Patents.

Mc-3                    The antibody known as Mc-3 and all forms and derivatives
                        thereof, including, without limitation, humanized and
                        non-humanised forms, its native form and radio-labelled
                        forms for a pharmaceutical formulation for human use,
                        and all fragments thereof.

Mc-3 Patents            Mc-3 Patents are the Patents described in Schedule 1
                        Part B; all substitutions, extensions, registrations,
                        confirmations, reissues, reexaminations, renewals and
                        like filings of any of the foregoing patents; all
                        non-United States Patents that are counterparts to any
                        of the foregoing patents and/or any patent applications
                        that gave rise to any of the foregoing patents, together
                        with all Patents claiming priority thereto and issuing
                        therefrom (but excluding the claims of any such Patents
                        to the extent directed to any new matter that may be
                        claimed in any continuation-in-part or similar
                        application outside the United States).

Net Sales Value         The [CONFIDENTIAL TREATMENT REQUESTED] of
                        Royalty-bearing Products sold or in any way transferred
                        of like kind by Somanta or Sub-Licensees or its
                        Affiliates to independent third parties in arm's length
                        transactions or, where the Royalty-bearing Products are
                        sold or in any way transferred, loaned or given and this
                        sale or transference is not at arm's length, the price
                        that would have been so [CONFIDENTIAL TREATMENT
                        REQUESTED] if it had been at arm's length, after
                        deduction of normal trade discounts actually granted and
                        any credits actually given and, provided the amounts are

                                       4
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                        separately charged on the relevant [CONFIDENTIAL
                        TREATMENT REQUESTED], any costs of packaging, insurance,
                        carriage and freight, any value added tax or other sales
                        tax, and any import duties or similar applicable
                        government levies.

NIH License             The license agreement between CRICC and the US National
                        Institutes of Health dated 9/29/2000.

Ongoing Clinical        Those clinical trials of Royalty bearing Products that
Trials                  are ongoing or planned with an approved protocol as of
                        the Commencement Date (i.e. that certain trial entitled
                        "Phase I Study of Combination Yttrium-90 MX-DTPA
                        Humanized BrE-3 Monoclonal Antibody (90-Y-MX-DTPA
                        huBrE-3 mAb; 90-Y huBrE-3) and Capecitabine in
                        Metastatic/Recurrent Breast Cancer").

Parties                 Immunodex and Somanta, and "Party" shall mean either of
                        them.

Patents                 Any and all patents and patent applications, including
                        any continuations, continuations in part, extensions,
                        reissues, divisions, and any patents, re-examination
                        certificates, foreign counterparts and other patents or
                        applications, supplementary protection certificates and
                        similar rights that are based on or derive priority from
                        the foregoing.

Royalty-bearing         Any and all products in the Field that are manufactured,
Products                sold or otherwise supplied by Somanta (or its Affiliate
                        or sublicensee hereunder) and contain BrE-3 and/or Mc-3
                        and are at any time within any Valid Claim of the BrE-3
                        Patents or the Mc-3 Patents (including, without
                        limitation, diagnostic imaging products and therapeutic
                        products), but excluding products based on the antigen
                        used to generate Mc-3 for use outside the Field (the
                        "Antigen Products").

                        It is understood and agreed that Immunodex retains all
                        rights with respect to such Antigen Products, which such
                        products shall not in any event be developed for use in
                        the Field.

Territory               The World.

Valid Claim             A claim of a patent application or patent that (a) in
                        the case of a pending claim, has been pending for no
                        more than [CONFIDENTIAL TREATMENT REQUESTED] and has not
                        been permanently abandoned or permanently permitted to
                        lapse, and (b) in the case of an issued claim, (i) has
                        not expired or been held invalid or unenforceable in a
                        final binding court decision from which no appeal can be

                                       5
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                        or is taken, or (ii) has not been admitted to be invalid
                        or unenforceable through reissue, disclaimer or
                        otherwise.

2.      Grant of rights, etc.

2.1     License. Subject to the terms hereof, Immunodex hereby grants Somanta,
        effective from the Commencement Date, the following sub-licenses in the
        Territory:

        (a)     An exclusive sub-license, with the right to sub-license solely
                as set forth in Section 2.2, under the BrE-3 Patents and Mc-3
                Patents solely as provided in Section 2.2; and

        (b)     an exclusive sub-license in the Field to use the Know-how
                relating to BrE-3 and an exclusive sub-license in the Field to
                use the Know-how related to Mc-3;

        (c)     If requested in writing by Somanta (within a reasonable time
                after the Commencement Date), Immunodex will seek to obtain for
                Somanta an exclusive sub-license of CRICC's rights and licenses
                under the Chelate MXDTPA License, including, without limitation
                a consent to such sub license from Coulter Corporation, the cost
                for such sub-license to be at Somanta's expense (this means,
                without limitation, that Somanta shall pay all sublicense issue
                fees, maintenance fees, milestones, royalties and other fees
                under the Chelate MXDTPA License that relate to the sublicense
                granted hereunder (including without limitation any activities
                in exercise of it), and shall pay such fees to Immunodex within
                2 weeks after receiving a written invoice for same, which
                written invoice Immunodex will provide no earlier than 2.5 weeks
                before the applicable payment is due to Coulter Corporation);
                and

        (d)     If requested in writing by Somanta (within a reasonable time
                after the Commencement Date), Immunodex will seek to obtain for
                Somanta a non-exclusive sub-license of CRICC's rights and
                licenses under the NIH License, including, without limitation a
                consent to such sub-license from the appropriate third parties,
                the cost for such sublicense to be at Somanta's expense (this
                means, without limitation, that Somanta shall pay all sublicense
                issue fees, maintenance fees, milestones, royalties and other
                fees under the NIH License that relate to the sublicense granted
                hereunder (including without limitation any activities in
                exercise of it), and shall pay such fees to Immunodex within 2
                weeks after receiving a written invoice for same, which written
                invoice Immunodex will provide no earlier than 2.5 weeks before
                the applicable payment is due to the NIH or its representative);

        (e)     in each case to develop, manufacture, have manufactured, use,
                sell, offer for sale and import Royalty-bearing Products for the
                Field.

                                       6
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

All sublicenses granted to Somanta hereunder are explicitly subject to the terms
and conditions of the agreement between Immunodex and/or CRICC and the third
party that has licensed Immunodex the rights being sublicensed and to the CRICC
- Immunodex license agreement as it exists as of the Effective Date.

2.2     Sub-licensing. Somanta shall be entitled to grant sub-licenses of its
        rights under this Agreement to any person, provided that:

        (a)     Somanta discloses to Immunodex not later than thirty (30) days
                before the date any such sublicense is entered into the identity
                of such proposed sub-licensee;

        (b)     the royalties and other consideration provided for in the
                sub-license shall be at an amount or rate which is not less than
                the amount or rate provided for in this Agreement to Immunodex
                (and in any event, Somanta shall remain obligated to pay
                Immunodex the milestones and royalties set forth herein based on
                the sublicensees' achievements and sales as if they were
                Somanta's);

        (c)     the sublicense does not violate and shall include obligations on
                the sub-licensee which are equivalent to or at least as
                stringent as the obligations on Somanta under this Agreement and
                does not violate any provision of the license agreement between
                Immunodex and CRICC with respect to the subject matter hereof as
                in effect on the Effective Date;

        (d)     At least 30 days prior to the proposed date of the grant of any
                sub-license Somanta shall provide to Immunodex a copy of
                proposed agreement;

        (e)     Immunodex shall have the right to reject any proposed
                sublicensee that Immunodex can demonstrate by competent written
                evidence (including, without limitation, evidence of such
                proposed sublicensee's debarment): [CONFIDENTIAL TREATMENT
                REQUESTED]; and

        (f)     within fifteen (15) days after the date of the sub-license
                agreement, Somanta delivers a copy of such sublicense agreement
                to Immunodex.

        (g)     any required consents from Immunodex's licensor(s) --and CRICC's
                to the extent than any sublicense is obtained and granted
                hereunder under Section 2.1(c) and/or 2.1(d) -- shall have been
                obtained (it being understood and agreed that Immunodex shall
                use all reasonable efforts to cause CRICC to give its consent if
                required under the CRICC-Immunodex license agreement dated April
                19, 2002 as such agreement exists as of the Effective Date).

        (h)     With respect to each sublicense granted by Somanta to a
                sublicensee hereunder (excluding any Affiliate of Somanta),
                Somanta agrees to pay to Immunodex a fee equal to [CONFIDENTIAL
                TREATMENT REQUESTED] of the initial cash fee and other (whether
                initial or not) monies received by Somanta from such sublicensee
                (other than royalties which are governed by Section 4.4 hereof)
                for the grant of a sublicense to the Licensed Patents and

                                       7
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                Know-how (such fee(s) and monies received from the sublicensee,
                "Sublicensing Revenue" and Immunodex's share thereof the
                "Sublicensing Fee"); provided, however, that:

                        (i) Immunodex's Sublicensing Fee based on a share of any
                        Sublicensing Revenue received in the form of
                        [CONFIDENTIAL TREATMENT REQUESTED] from a sublicensee
                        [CONFIDENTIAL TREATMENT REQUESTED] shall not in any
                        event exceed [CONFIDENTIAL TREATMENT REQUESTED];

                        (ii) if the Sublicensing Fee based on the [CONFIDENTIAL
                        TREATMENT REQUESTED] from any particular licensee would
                        be less than [CONFIDENTIAL TREATMENT REQUESTED], then
                        Somanta shall pay Immunodex [CONFIDENTIAL TREATMENT
                        REQUESTED] on the date of [CONFIDENTIAL TREATMENT
                        REQUESTED] and [CONFIDENTIAL TREATMENT REQUESTED] on
                        each of the [CONFIDENTIAL TREATMENT REQUESTED] of such
                        date (for a total aggregate payment of [CONFIDENTIAL
                        TREATMENT REQUESTED] in lieu of such Sublicensing Fee
                        based on such [CONFIDENTIAL TREATMENT REQUESTED]; and

                        (iii) with respect to Sublicensing Fees based on
                        Sublicensing Revenues other than [CONFIDENTIAL TREATMENT
                        REQUESTED] (for example but without limitation, in the
                        form of [CONFIDENTIAL TREATMENT REQUESTED] received by
                        Somanta in a particular calendar year, Somanta shall be
                        entitled to [CONFIDENTIAL TREATMENT REQUESTED] the
                        entire amount of [CONFIDENTIAL TREATMENT REQUESTED] with
                        respect to the same time period under [CONFIDENTIAL
                        TREATMENT REQUESTED] such that [CONFIDENTIAL TREATMENT
                        REQUESTED] under this subsection 2.2(h)(iii) unless the
                        [CONFIDENTIAL TREATMENT REQUESTED] exceeds the
                        [CONFIDENTIAL TREATMENT REQUESTED] and then only to the
                        extent [CONFIDENTIAL TREATMENT REQUESTED] exceeds the
                        [CONFIDENTIAL TREATMENT REQUESTED]; provided, however,
                        that the [CONFIDENTIAL TREATMENT REQUESTED] of
                        Sublicensing Fees [CONFIDENTIAL TREATMENT REQUESTED] (to
                        avoid any doubt, this means other than through
                        [CONFIDENTIAL TREATMENT REQUESTED]) pursuant to this
                        subsection 2.2(h)(iii) in [CONFIDENTIAL TREATMENT
                        REQUESTED] to [CONFIDENTIAL TREATMENT REQUESTED] an
                        amount equal to [CONFIDENTIAL TREATMENT REQUESTED], the
                        amount paid or to be paid to Immunodex pursuant to
                        [CONFIDENTIAL TREATMENT REQUESTED], whichever is
                        applicable for that sublicense. This [CONFIDENTIAL

                                       8
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                        TREATMENT REQUESTED] per sublicense is explicitly not
                        subject to [CONFIDENTIAL TREATMENT REQUESTED] of any
                        [CONFIDENTIAL TREATMENT REQUESTED].

                Notwithstanding the definition of Sublicensing Revenues provided
                above, Sublicensing Revenues do not include and Immunodex shall
                not receive any share of payments with respect to monies (or
                equivalent value) received by Somanta which are (a) for future
                (after Somanta grants the sublicense) support, at fair market
                value, of Somanta's laboratory research, screening and
                development programs or for reimbursement of any amounts to be
                (and ultimately actually) expended on the foregoing pursuant to
                and after the signing of a written agreement requiring such
                expenditure, (b) equity investments in Somanta at fair market
                value (it being understood that any premium paid with respect to
                such an equity investment made in connection with such a
                sublicense would be included in Sublicensing Revenues and
                subject to payment of a Sublicensing Fee hereunder), (c) bona
                fide loans or other financing provided at market-based rates
                (and specifically excluding any loan forgiveness), (d) payments
                to Somanta in consideration of the grant of rights to any other
                intellectual property of Somanta provided however that no
                greater than one half (1/2) the value of any licensing deal or
                relationship may be attributed to such other Intellectual
                Property, and (e) any prepayments on any of the items listed in
                subsections (a), (b), (c) or (d) above. This paragraph, however,
                shall not be used to contradict proviso (ii) stated above in
                this Section 2.1(h) and Somanta shall pay Immunodex at least the
                amount set forth in such proviso with respect to each sublicense
                granted hereunder.

2.3     Supply of materials and materials related to Know-how.

2.3.1   Immunodex shall disclose, provide, transfer or make available for
        transfer (as applicable and noted below) to Somanta or its nominee:

        (a)     Within five (5) days after deposit of Escrow Amount 1 (set forth
                in Section 4.1(c)) into the escrow account (and provided that
                the payment of Section 4.1(a) has also been paid, in this case
                directly to Immunodex) Immunodex shall make available at CRICC's
                facility 10 frozen vials from the working cell bank containing
                huBre-3v1 cells to Somanta (or its carrier) for Somanta (or its
                carrier) to provide to one of the following third parties:
                [CONFIDENTIAL TREATMENT REQUESTED] for the purpose of verifying
                the viability of such cell line as to [CONFIDENTIAL TREATMENT
                REQUESTED]. Immunodex shall be entitled to provide the cell
                lines and all antigens and other materials it may agree to
                provide for such testing in coded fashion, and Somanta shall not
                reveal the identity of the cell lines and antigens to any third
                party involved in the testing. Somanta shall be responsible at
                its expense for making and effecting the shipping arrangements.
                Somanta shall be responsible to select one of these third-party
                laboratories and to pay for their services. Such third party
                shall be under reasonable confidentiality and non-use
                obligations to Immunodex. Such third party shall complete the
                testing and provide its report (described below) within two (2)

                                       9
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                months after Immunodex makes such 10 vials available. Such third
                party upon completion of all relevant testing, shall provide to
                the Parties a detailed written report related to the tests
                conducted and a conclusion as to each of the foregoing 3 factors
                (i) - (iii). If the report concludes that the cell line:
                [CONFIDENTIAL TREATMENT REQUESTED], the Parties shall promptly
                instruct the escrow agent to release Escrow Amount 1 to
                Immunodex. Within ten (10) days thereafter, Immunodex shall
                transfer to Somanta the majority of the quantities of the
                huBrE-3 master cell and working cell banks in its possession,
                provided however that Immunodex reserves the right to retain
                reasonable quantities of samples of such cell banks (x) for
                non-clinical research while the licenses to Somanta for BrE-3
                remain in effect, and (y) to use for any and all purposes if
                Somanta's licenses to BrE-3 hereunder terminate. If the report
                concludes that the cell line [CONFIDENTIAL TREATMENT REQUESTED],
                the Parties shall promptly instruct the escrow agent to release
                Escrow Amount 1 to Somanta and Immunodex shall promptly refund
                to Somanta the entire amount paid to Immunodex pursuant to
                Section 4.1(a). The Parties hereby agree to be bound by the
                conclusions set forth in the third party's report;

        (b)     Prior to the earlier of: (i) six months after the Commencement
                Date or (ii) 5 business days after receiving written notice from
                Somanta of the Funding, and provided in each case that Somanta
                has paid Escrow Amount 2 into the escrow account and paid the
                payment of Section 4.1(b) directly to Immunodex, Immunodex shall
                make available to Somanta (or its carrier) at CRICC's facility
                10 frozen vials from the working cell bank containing huMc-3v1
                cells for Somanta (or its carrier) to provide to one of the
                following third parties: [CONFIDENTIAL TREATMENT REQUESTED] for
                the purpose of verifying the viability of such cell line as to
                [CONFIDENTIAL TREATMENT REQUESTED]. Immunodex shall be entitled
                to provide the cell lines and all antigens and other materials
                it may agree to provide for such testing in coded fashion, and
                Somanta shall not reveal the identity of the cell lines and
                antigens to any third party involved in the testing. Somanta
                shall be responsible at its sole expense for making and
                effecting the shipping arrangements. Somanta shall be
                responsible to select one of these third-party laboratories and
                to pay for their services. Such third party shall be under
                reasonable confidentiality and non-use obligations to Immunodex.
                Such third party shall complete the testing and provide its
                report (described below) within two (2) months after Immunodex
                makes such 10 vials available. Such third party upon completion
                of all relevant testing, shall provide to the Parties a detailed
                written report related to the tests conducted and a conclusion
                as to each of the foregoing viability factors. If the report
                concludes that the cell line [CONFIDENTIAL TREATMENT REQUESTED],
                then the Parties shall promptly instruct the escrow agent to
                release Escrow Amount 2 to Immunodex. Within ten (10) days
                thereafter, Immunodex shall transfer to Somanta the majority of
                the quantities of the huMc-3 master cell bank and working cell
                bank in its possession; provided, however that Immunodex
                reserves the right to retain reasonable quantities of samples of
                such cell banks (x) for non-clinical research while the licenses
                to Somanta for Mc-3 remain in effect, and (y) to use for any and
                all purposes if Somanta's licenses to Mc-3 hereunder terminate.

                                       10
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                If the report concludes that the cell line: [CONFIDENTIAL
                TREATMENT REQUESTED], then the Parties shall promptly instruct
                the escrow agent to release Escrow Amount 2 to Somanta. The
                Parties hereby agree to be bound by the conclusions set forth in
                the third party's report; and

        (c)     Within 30 days after the Commencement Date, authorize (in
                writing) Immunodex's third-party contractors for BrE-3 (these
                are: [CONFIDENTIAL TREATMENT REQUESTED]) to disclose
                manufacturing information, SOP's, assays and protocols
                (including those related to radio-labeling), that are within the
                Know-How to Somanta, (and, to the extent Controlled by Immunodex
                as of the Effective Date, provide all necessary rights to use
                such information, including, without limitation to avoid any
                doubt, to the extent Controlled by Immunodex, any rights under
                any patent/cell depository agreements with American Tissue
                Culture Collection or any other third party) and assist Somanta
                in obtaining any such information, SOP's, assays and/or
                protocols; and

        (d)     Within 30 days after the Commencement Date, disclose the
                contents of all laboratory, pre-clinical data, animal studies
                data, stability studies, sterility studies, regulatory filings,
                clinical data (including without limitation such data on a Phase
                I study conducted by CRICC entitled Phase I Study of Yttrium 90
                labeled humanized Monoclonal Antibody BrE-3 and Indium In 111
                Humanized Monoclonal antibody BrE-3 followed by autologous bone
                marrow or Peripheral Blood Stem Cell Transplantation in Patients
                with Metastatic Breast Cancer) and any correspondence with the
                U.S. Food and Drug Administration or equivalent foreign body, in
                each case related to either BrE-3 or Mc-3. To avoid any doubt,
                any CRICC and/or Immunodex or other investigator-sponsored IND
                for any Royalty-bearing Product is not required to be
                transferred to Somanta (or its nominee), and it is intended by
                the Parties that same shall be retained by CRICC and/or
                Immunodex, as the case may be (although the results of clinical
                trials under them shall be disclosed to Somanta to the extent
                set forth in a separate written agreement between Somanta and
                CRICC related to such trials). Both parties recognize that as of
                the Commencement Date, given the stage of research and
                development on Mc-3, there is no correspondence with the FDA
                regarding Mc-3, thus none will be provided.

        (e)     To avoid any doubt, pursuant to the Know-how disclosure
                provisions of this Agreement, Immunodex is disclosing to Somanta
                the procedures used to produce the current clinical materials.
                Immunodex is under no obligation to develop a scaled-up method
                of production for either BrE-3 or Mc-3 or both, and has no
                process development nor manufacturing process "trouble-shooting"
                obligations hereunder. Somanta is solely responsible for such
                work, in accordance with and without limiting its
                responsibilities under Section 3.3.

2.3.2.  Somanta agrees to adhere to any obligations of confidentiality,
        non-distribution and limited use that relate to the materials delivered
        by Immunodex to Somanta pursuant to this Section 2.3. To protect against
        any unauthorized distribution of any cell or cell culture, Somanta will
        maintain a log related to the use, distribution and storage of any cell

                                       11
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

        line delivered by Immunodex to Somanta pursuant to this Section 2.3.
        Somanta must disclose quarterly to Immunodex such log and all updates,
        changes and corrections to it. Somanta will obtain insurance to cover
        the loss or destruction of the GMP Materials in an amount not to exceed
        [CONFIDENTIAL TREATMENT REQUESTED], and will name Immunodex as an
        additional insured under such policy.

        Without limiting any other restrictions and obligations set forth in
this Agreement, Somanta and its Affiliates and sublicensees hereunder shall not
use any cell lines or other materials provided hereunder, nor any derivatives
(including without limitation progeny of cells) of any such materials, outside
the scope of the sublicenses granted Somanta hereunder.

2.4     Reservation of rights. Immunodex reserves all rights outside the Field
        and the non-exclusive right for itself and other academic and/or
        not-for-profit researchers, to use the Know-how and to practice the
        subject matter of the BrE-3 and Mc-3 Patents in the Field for the
        purposes of academic, non-commercial research (which may, to avoid
        doubt, include clinical trials), subject to the confidentiality
        provisions set out in clause 3 below; provided, however, that any such
        other academic and/or not-for-profit researcher may not sublicense such
        rights to any third party not itself falling within the category of
        entities for which rights are reserved (i.e. they may only sublicense to
        other academics and not-for-profits).

2.5     Security Interest. To secure Somanta's obligations under this Agreement,
        Somanta hereby grants to Immunodex a security interest in each of the
        BrE-3 and Mc-3 cell lines transferred to Somanta pursuant to this
        Agreement.

3.      Know-how and Confidential Information

3.1     Provision of Know-how. To the extent the disclosure is not addressed in
        Section 2.3.1, within 30 days after the date of this Agreement,
        Immunodex shall disclose to Somanta all Know-how (in its legal
        possession and Control as of the Effective Date) that Immunodex has not
        previously disclosed to Somanta and that is necessary or desirable to
        enable Somanta to undertake the further development of the
        Royalty-bearing Products. The way in which the Know-How will be
        disclosed shall consist of, first, up to 2 days from each of Drs.
        Roberto Ceriani and Jerry Peterson, and thereafter, after Somanta has
        reviewed the Know-how thus transferred, up to one additional day from
        each such person to the extent requested by Somanta, all at no
        additional consideration for their time (if there are travel expenses
        for travel required by Somanta, Somanta will cover these expenses). Any
        further consultation by such Drs. shall be pursuant to the consulting
        agreements that CRICC and Dr. Roberto Ceriani are entering into with
        Somanta contemporaneously with this Agreement.

3.2     Status of Know-how. Somanta acknowledges that the Know-how is at an
        early stage of development. Accordingly, specific results cannot be
        guaranteed and any results, materials, information or other items
        (together "Delivered Items") provided under this Agreement are provided
        "as is" and without any express or implied warranties, representations
        or undertakings. As examples, but without limiting the foregoing,

                                       12
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

        Immunodex does not give any warranty that Delivered Items are of
        merchantable or satisfactory quality, are fit for any particular
        purpose, comply with any sample or description, or are viable,
        uncontaminated, safe or non-toxic, except as required by Section 2.3.1
        (a) and (b).

3.3     Responsibility for development of Royalty-bearing Products. Somanta
        shall be solely and exclusively responsible for the technical and
        commercial development and manufacture of Royalty-bearing Products and
        for incorporating any modifications or developments thereto that may be
        necessary or desirable and for all Royalty-bearing Products sold or
        supplied, and accordingly Somanta shall indemnify Immunodex in the terms
        of Clause 7.4 (without limiting such Clause).

3.4     Use of Know-how. Somanta undertakes that for a period of [CONFIDENTIAL
        TREATMENT REQUESTED] from the Commencement Date or for so long as any
        substantial part of the Know-how remains subject to the obligations of
        confidence of Clause 3.5, whichever is the shorter, it will not use the
        Know-how for any purpose except as expressly licensed hereby and in
        accordance with the provisions of this Agreement.

3.5     Confidentiality obligations. Each Party ("Receiving Party") undertakes:

        (a)     to maintain as secret and confidential all know-how and other
                technical or commercial information obtained directly or
                indirectly from the other Party ("Disclosing Party") in the
                course of or in anticipation of this Agreement and to respect
                the Disclosing Party's rights therein,

        (b)     to use the same exclusively for the purposes of this Agreement,
                and

        (c)     to disclose the same only to those of its employees, contractors
                and licensees or sublicensees pursuant to this Agreement (if
                any) to whom and to the extent that such disclosure is
                reasonably necessary for the purposes of this Agreement,
                including clinical investigators, institutional review boards
                and to any regulatory body for the purpose of obtaining
                registration of or regulatory approval for a Royalty-bearing
                Product.

3.6     Exceptions to obligations. The provisions of Clause 3.5 shall not apply
        to know-how and other information which the Receiving Party can
        demonstrate by reasonable, written evidence:

        (a)     was, prior to its receipt by the Receiving Party from the
                Disclosing Party, in the possession of the Receiving Party and
                at its free disposal; or

        (b)     is subsequently disclosed to the Receiving Party without any
                obligations of confidence by a third party who has not derived
                it directly or indirectly from the Disclosing Party; or

                                       13
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

        (c)     is or becomes generally available to the public through no act
                or default of the Receiving Party or its agents, employees,
                Affiliates or licensees or sublicensees; or

        (d)     the Receiving Party is required to disclose to the courts of any
                competent jurisdiction, or to any government regulatory agency
                or financial authority, provided that the Receiving Party shall
                (i) inform the Disclosing Party as soon as is reasonably
                practicable, and (ii) at the Disclosing Party's request seek to
                persuade the court, agency or authority to have the information
                treated in a confidential manner, where this is possible under
                the court, agency or authority's procedures (iii) limit its
                disclosure and use to the extent required by the court or
                government regulatory agency; or

        (e)     in the case of information disclosed by Immunodex to Somanta, is
                disclosed to actual or potential customers for Royalty-bearing
                Products in so far as such disclosure is reasonably necessary to
                promote the sale or use of Royalty-bearing Products, provided
                that the customers sign a written confidentiality undertaking at
                least as restrictive as Clauses 3.5 and 3.6.

3.7     Disclosure to employees. The Receiving Party shall procure that all of
        its employees, contractors, licensees or sub-licensees pursuant to this
        Agreement (if any) who have access to any of the Disclosing Party's
        information to which Clause 3.5 applies, shall be made aware of and
        subject to these obligations and shall have entered into written
        undertakings of confidentiality at least as restrictive as Clauses 3.5
        and 3.6 and which apply to the Disclosing Party's information.

4.      Payments

4.1.    Initial consideration. Somanta shall:

        (a)     on or before the date that is ten (10) days after the date of
                this Agreement, pay to Immunodex an initial license fee of
                [CONFIDENTIAL TREATMENT REQUESTED]; provided, however, that this
                initial license fee of [CONFIDENTIAL TREATMENT REQUESTED] shall
                be promptly refunded to Somanta in full in accordance with
                Section 2.3.1(a) if Immunodex is unable to deliver the BrE-3
                cell line in a viable condition.

        (b)     on the earlier of (i) the date that is six (6) months after the
                date of this Agreement, or (ii) upon the closing of a Funding
                pay to Immunodex an additional license fee of [CONFIDENTIAL
                TREATMENT REQUESTED].

        (c)     promptly after the date of this Agreement, deposit into an
                escrow account with a national banking institution [CONFIDENTIAL
                TREATMENT REQUESTED] ("Escrow Amount 1") to be distributed in
                accordance with Section 2.3.1(a);

        (d)     on the earlier of (i) the date that is six (6) months after the
                date of this Agreement, or (ii) upon the closing of a Funding,

                                       14
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                pay into an escrow account with a national banking institution a
                one-time fee of [CONFIDENTIAL TREATMENT REQUESTED] ("Escrow
                Amount 2") to be distributed in accordance with Section
                2.3.1(b).

4.2     License Maintenance. On each anniversary of the date of this Agreement,
        Somanta shall pay Immunodex a license maintenance fee of [CONFIDENTIAL
        TREATMENT REQUESTED], until the First Commercial Sale of a
        Royalty-bearing Product at which time this fee will be automatically
        reduced to [CONFIDENTIAL TREATMENT REQUESTED] and shall be in
        consideration of the maintenance of the license to the BrE-3 Patents or
        the Mc-3 Patents, as the case may be, that do not cover the first
        Royalty-bearing Product (the "Non-Commercialized Patents"); provided,
        however, that Somanta's obligation to pay this [CONFIDENTIAL TREATMENT
        REQUESTED] license maintenance fee with respect to the
        Non-Commercialized Patents shall terminate and be of no further force or
        effect upon the earlier of: (i) approval of a Royalty-bearing Product by
        the U.S. Food and Drug Administration covered by the Non-Commercialized
        Patents, or (ii) termination of the license with respect to the
        Non-Commercialized Patents; and provided, further, that nothing in the
        choice of defined term of "Non-Commercialized Patents" shall be read to
        imply that Somanta is not required to be diligent with respect to the
        subject matter of the patent applications and patents included within
        such term.

4.3     Payment terms. Except for the payment set forth in clause 4.1(a) above
        (which is refundable solely under the circumstances and to the extent
        set forth in Section 2.3.1(a), all above payments from Somanta to
        Immunodex are non-refundable and are not considered advances against
        royalty or other payments due hereunder. The royalty payments to be made
        pursuant to Section 4.4 below shall be made within thirty (30) days
        after the end of each calendar quarter in which Royalty-bearing Products
        are sold, beginning with the quarter in which the First Commercial Sale
        is made.

4.4.    Royalties. Somanta shall pay Immunodex, on a country-by-country basis, a
        royalty equal to [CONFIDENTIAL TREATMENT REQUESTED] of Net Sales Value
        of any Royalty-bearing Product that comes within the scope of a Valid
        Claim of the BrE-3 Patents and [CONFIDENTIAL TREATMENT REQUESTED] of Net
        Sales Value of any Royalty-bearing Product that comes within the scope
        of a Valid Claim of the Mc-3 Patents. Such royalties shall be payable on
        each Royalty-bearing Product from the date of First Commercial Sale of
        such Royalty-bearing Product in such country until the later of (a) the
        expiration of the last Valid Claim covering such Royalty-bearing Product
        or its manufacture or use, and (b) [CONFIDENTIAL TREATMENT REQUESTED]
        after such date of first Commercial Sale; provided however, that if the
        royalty is being paid based on the time in (b) but the time in (a) has
        expired, then the applicable royalty rate shall be reduced to
        [CONFIDENTIAL TREATMENT REQUESTED] of the regular rate prior to patent
        expiry. If Somanta markets a combination product that combines BrE-3
        with Mc-3 Antibodies then the [CONFIDENTIAL TREATMENT REQUESTED] rate
        shall apply to the entire Net Sales Value of the combination product.

4.5.    All sums due under this Agreement:

        (a)     are exclusive of Value Added Tax which, where applicable, will
                be paid by Somanta to Immunodex in addition;

                                       15
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

        (b)     shall be paid in U.S. dollars by check or wire transfer made
                payable to Immunodex, Inc., and in the case of sales or
                sub-license income received by Somanta in a currency other than
                U.S. dollars, the royalty shall be calculated in the other
                currency and then converted into equivalent U.S. dollars at the
                buying rate of such other currency as quoted by The Wall Street
                Journal, Western Edition, as at the close of business on the
                last business day of the quarterly period with respect to which
                the payment is made;

        (c)     shall be made without deduction of income tax or other taxes
                charges or duties that may be imposed, except insofar as Somanta
                is required to deduct the same to comply with applicable laws.
                The Parties shall cooperate and take all steps reasonably and
                lawfully available to them, at the expense of Immunodex to avoid
                deducting such taxes and to obtain double taxation relief. If
                Somanta is required to make any such deduction it shall provide
                Immunodex with such certificates or other documents as it can
                reasonably obtain to enable Immunodex to obtain appropriate
                relief from double taxation of the payment in question; and

        (d)     shall be made by the due date set forth in this Agreement,
                unless otherwise agreed to by Immunodex (with Immunodex being
                entitled to withhold its agreement in its sole discretion).

4.6.    If, at any time during the continuation of this Agreement, Somanta is
        prohibited from making any of the payments required hereunder by a
        governmental authority in any country then Somanta will within the
        prescribed period for making the said payments in the appropriate manner
        use its best endeavours to secure from the proper authority in the
        relevant country permission to make the said payments and will make them
        within 7 days of receiving such permission. If such permission is not
        received within 30 (thirty) days of Somanta making a request for such
        permission then, at the option of Immunodex, Somanta shall deposit the
        royalty payments due in the currency of the relevant country either in a
        bank account designated by Immunodex within such country or such royalty
        payments shall be made to an associated company of Immunodex designated
        by Immunodex and having offices in the relevant country designated by
        Immunodex.

4.7.    Records

4.7.1.  Somanta shall keep at its normal place of business detailed and up to
        date records and accounts showing the quantity, description and value of
        Royalty-bearing Products sold by it, and the amount of sublicensing
        revenues received by it in respect of Royalty-bearing Products, on a
        country by country basis, and being sufficient to ascertain the
        royalties due under this Agreement for a period of at least five (5)
        years after the time periods to which the records relate.

4.7.2.  Somanta shall make such records and accounts available, on five (5)
        business days notice, for inspection during business hours by an
        independent public accountant nominated by Immunodex for the purpose of

                                       16
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

        verifying the accuracy of any statement or report given by Somanta to
        Immunodex under this clause 4. The accountant shall be required to keep
        confidential all information learnt during any such inspection, and to
        disclose to Immunodex only such details as may be necessary to report on
        the accuracy of Somanta's statement or report. Immunodex shall be
        responsible for the accountant's charges, unless the report reveals an
        underpayment of five percent (5%) or more for the periods audited, in
        which case Somanta shall promptly pay the difference as well as the
        public accountant's full fees.

4.7.3.  Somanta shall ensure that Immunodex has the same rights as those set out
        in this Clause 4.7 in respect of any licensee or license or sub-licensee
        of Somanta that is licensed or sub-licensed under the Patents and/or
        Know-how pursuant to this Agreement.

4.8.    Transaction Fee. Somanta will reimburse Immunodex for its legal fees
        incurred in connection with the negotiation of this Agreement in an
        amount not to exceed [CONFIDENTIAL TREATMENT REQUESTED] within thirty
        (30) after Immunodex provides Somanta written documentation
        substantiating the actual amount of such fees. This amount is
        non-refundable and this payment obligation survives notwithstanding any
        termination of this Agreement under circumstances described in Section
        2.3.1 or otherwise.

5.      Commercialisation

5.1.    Somanta shall use commercially reasonable efforts (defined as the
        efforts a typical biopharmaceutical company would devote to a product of
        similar potential at a similar stage of development that has not been
        in-licensed in order to develop and commercialize it in a sustained and
        diligent manner without interruption, pause or delay), at its sole cost
        and expense, to develop and commercially exploit Royalty-bearing
        Products, including, without limitation, all laboratory and clinical
        studies performed hereunder, it being understood that any and all costs
        and expenses incurred by Somanta in connection with the development of
        any Royalty-bearing Product shall not be credited or offset against any
        other payments that may be due and owing from Somanta to Immunodex
        hereunder. Commercially reasonable efforts with respect to
        Royalty-bearing Products covered by the Bre-3 Patents or the Mc-3
        Patents, as the case may be, shall include without limitation Somanta
        carrying out the following activities, with respect to Royalty-bearing
        Products covered by the Bre-3 Patents or Mc-3 Patents, as the case may
        be, on or before the agreed upon amount of time has elapsed after the
        date of this Agreement as indicated in the Table below (n/a indicates
        such milestone is not applicable to such Royalty-bearing Product
        development):

                                       17
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

     --------------------------------------------------------------------------
     Milestone                 BrE-3 -                  Mc-3 -
     ---------                 --------                 -------
     [CONFIDENTIAL TREATMENT   [CONFIDENTIAL TREATMENT  [CONFIDENTIAL TREATMENT
     REQUESTED]                REQUESTED]               REQUESTED]
     --------------------------------------------------------------------------

     --------------------------------------------------------------------------

     --------------------------------------------------------------------------

     --------------------------------------------------------------------------

     --------------------------------------------------------------------------

     --------------------------------------------------------------------------

     --------------------------------------------------------------------------

* Each clinical study shall be deemed initiated at such time as Somanta has
entered into an agreement to conduct that specific trial with the applicable
institution at which the clinical study will be conducted.

** The parties will commence negotiating in good faith such diligence milestone
within three (3) months time after the receipt of sufficient data from the
animal studies related to Mc-3, such negotiations to conclude no later than nine
(9) months after such negotiations begin. At such time as the parties have
agreed upon diligence milestones related to the development of Mc-3 (at some
time within such nine (9) months), this agreement will be amended to include
such additional diligence milestones.

If Somanta fails to meet any of the dates set forth in the table of milestones
above, then Immunodex has the right to terminate this Agreement (with respect to
the applicable program) under Section 8.3.2, and, subject to the final paragraph
of this subsection below, Somanta shall pay the following fee based on time
elapsed after the Commencement Date (and, subject to the final paragraph of this
subsection below, any termination by Somanta under Section 8.3.1 without meeting
these milestones shall be deemed a termination by Immunodex under Section 8.3.2
and shall not be a means for evading the diligence requirements or the
cancellation fees):

Time elapsed from Commencement Date
(one year equals 365 days, except for leap years which have 366 days)
                                            BrE-3            Mc3
                                            Payment          Payment

1 year   [CONFIDENTIAL TREATMENT REQUESTED]
2 year   [CONFIDENTIAL TREATMENT REQUESTED]
3 year   [CONFIDENTIAL TREATMENT REQUESTED]
4 year   [CONFIDENTIAL TREATMENT REQUESTED]
5 year   [CONFIDENTIAL TREATMENT REQUESTED]

Notwithstanding anything to contrary herein, Somanta shall not be obligated to
make any payment under this Section 5.1 if this Agreement is terminated (as to
Bre-3, Mc-3, or both) as a result of any of the following:

        1) if Somanta discontinues the development of the applicable
Royalty-bearing Product due to the negative results of any toxicity testing or
any clinical trial that the FDA indicates would preclude further testing of the

                                       18
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

applicable Royalty Product(s), or with respect to animal testing of Mc3, that
would preclude continued development or would prevent non-rejection of an IND
for an Mc3-based Royalty-bearing Product based on FDA guidance or the prevailing
standards that FDA applies;

        2) if Somanta discontinues the development of the applicable
Royalty-bearing Product because a third party is granted orphan drug status by
the FDA for a Yttrium-labelled or -linked monoclonal antibody targeting the same
antigen (as BrE-3 or Mc-3, as applicable) that would be considered the same drug
under applicable law for orphan drug exclusivity purposes, the orphan drug
designation is to treat the same indication for which Somanta's applicable
Royalty-bearing Product is being clinically tested hereunder and the development
of such other drug is at a stage such that such other party will be in a
position to file a BLA or NDA with respect to such other drug prior to the time
that Somanta will be in a position to file a BLA or NDA with respect to the
applicable Royalty-bearing Product (i.e., the entity that benefits from such
orphan drug status designation is further along in clinical development than
Somanta);

        3) If the remote possibility occurs that -- after exhausting all
reasonable efforts to optimize production of Royalty-bearing Products to achieve
commercially viable yields of BrE-3 and/or Mc-3 -- Somanta still does not
achieve commercially viable yields of the antibody(ies) for which it is
terminating (BrE-3 and/or Mc-3 as applicable). This remote possibility will be
deemed to have occurred if:

                (a) Somanta fails to obtain a commercially viable manufacturing
yield for the relevant antibody(ies) under cGMP conditions, only after Somanta
has tried for at least [CONFIDENTIAL TREATMENT REQUESTED] to increase antibody
production by all currently available methods (these must include but are not
limited to the following techniques and procedures: genetic engineering
approaches, gene splicing, introduction of enhancers, re-hybridization with new
hybridoma partner and techniques to magnify protein production in cells and
hybridomas, gene grafting and redundant gene deletion, and then

                (b) Having concluded that (a) has occured, Somanta must notify
Immunodex in writing and within 30 days assemble a panel of 2 to 3 academic
investigators with relevant expertise and specialties. These academic experts
will have 60 days to provide a report proposing new alternative approaches to be
followed by Somanta to seek to obtain commercially viable yields of the relevant
antibody(ies) under cGMP conditions. Somanta shall then dedicate at least
[CONFIDENTIAL TREATMENT REQUESTED] at a total budget of at least [CONFIDENTIAL
TREATMENT REQUESTED] to test the panel recommendations. It will be then and only
then after these last [CONFIDENTIAL TREATMENT REQUESTED] of testing that Somanta
can terminate this Agreement with respect to the relevant antibody(ies) (BrE-3
and/or Mc-3) without incurring a termination penalty to Immunodex as specified
above in this Section 5.1, on the basis of a failure to obtain commercially
viable yields of such antibody(ies) under cGMP conditions

A "commercially viable yield" for BrE-3 shall be deemed to have been achieved if
a cell line produces such antibody at a level of at least [CONFIDENTIAL
TREATMENT REQUESTED] in then state-of-the-art production equipment and
facilities. Similarly, a "commercially viable yield" for Mc-3 shall be deemed to

                                       19
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

have been achieved if a cell line produces such antibody at a level of at least
[CONFIDENTIAL TREATMENT REQUESTED] in then state-of-the-art production equipment
and facilities; or

        (4) If, with respect to BrE-3, the report delivered by the third party
testing facility as set forth in Section 2.3.1(a) results in Escrow Amount 1
being released to Somanta, and if, with respect to Mc-3, the report delivered by
the third party testing facility as set forth in Section 2.3.1(b) results in
Escrow Amount 2 being released to Somanta.

5.2. Without prejudice to the generality of Somanta's obligations under Clause
5.1, Somanta shall provide at least semi-annually to Immunodex an updated,
written Development Plan, showing all past, current and projected activities
taken or to be taken by Somanta to bring Royalty-bearing Products to market and
sell Royalty-bearing Products worldwide, such Development Plan to be submitted
to Immunodex by May 1 and November 1 of each year. With regard to the items to
be determined, after Somanta has consulted with the FDA regarding the need
and/or extent of such studies, the parties shall amend this agreement to include
mutually agreeable and reasonable time frames related to the completion of such
studies, if necessary.

5.3. Clinical Trials. Somanta intends to enter into an amended and restated
Clinical Trial Agreement with CRICC for the purpose of enabling CRICC to sponsor
clinical trials related to potential Royalty-bearing Products; provided,
however, that any academic institution or hospital conducting such trial or
trials must have appropriate approval by their respective Institutional Review
Board and approval by the U.S. Food and Drug Administration for conducting such
clinical trial or trials. Furthermore, no patient will be treated in any such
clinical trial unless the applicable institution or hospital at which such trial
is conducted releases in writing each of Immunodex and CRICC from any and all
liability associated with the conduct of such clinical trial or trials.

6.      Intellectual property

6.1.    Obtain and maintain the Patents. Somanta shall at its own cost and
        expense (and through counsel of its choosing, which shall initially be
        DLA Piper Rudnick Gray Cary (by or under the supervision of Lisa Haile)
        and shall be through counsel reasonably acceptable to Immunodex and if
        Somanta changes law firms):

        (a)     prosecute and endeavour to issue patents on each patent
                application within the BrE-3 Patents and Mc-3 Patents so as to
                secure the broadest claim coverage reasonably available on the
                basis of these applications; and

        (b)     pay all renewal, annuity and maintenance fees in respect of the
                BrE-3 Patents and Mc-3 Patents as and when due and provide
                notice and evidence to Immunodex of such payments within 30 days
                of the effective date of payment;

        provided that if Somanta wishes to abandon any such application or not
        to maintain any such patent within the Licensed Patents (or to cease
        funding such application or Patent) it shall give thirty (30) days'
        prior written notice to Immunodex and on the expiry of such notice
        period Somanta shall lose all licensing rights to such patent

                                       20
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

        application or patent identified in the notice, and Immunodex may
        thereafter continue to pursue and maintain such patent applications and
        patents.

        (c)     Immunodex will promptly after the date of this Agreement
                disclose a copy of all relevant documentation, within its legal
                possession and Control related to the prosecution or maintenance
                of any patent or patent applications listed on Schedule 1 to
                patent counsel identified by Somanta.

        With respect to Licensed Patent prosecution conducted by Somanta under
        Section 6.1(a), Somanta shall provide to Immunodex no later than thirty
        (30) days after the date of anticipated filing (including without
        limitation of responses to office actions and the like) a draft of the
        anticipated filing. When Somanta provides the draft, it shall disclose
        such anticipated date of filing to Immunodex. Somanta shall reasonably
        consider and incorporate to the extent reasonable Immunodex's comments
        thereon received no later than five (5) days before the date of
        anticipated filing and shall confer with Immunodex in person or by
        telephone regarding any comments that Somanta does not wish to
        incorporate.

        The Parties' agreements regarding patent prosecution and maintenance are
        subject to the terms of the written agreements by which Immunodex
        derives rights in the Licensed Patents, to the full extent applicable.

6.2     Infringement of the Patents

        6.2.1 Notice. Each Party shall notify the other in writing of any
        suspected infringement of any Licensed Patent(s) by commercial
        activities within the Field, promptly after learning of such
        infringement or challenge.

        6.2.2 Action Against Infringement in the Field. As between the Parties,
        Somanta shall have the first right to prosecute and shall bear all
        expenses associated with all claims against third parties for
        infringement during the term within the Field of the Licensed Patent(s);
        provided, however that Somanta's action must be limited to pursuit and
        prevention of infringement within the Field that is competitive with
        Somanta's activities under this Agreement. If Somanta does not take
        action to end the infringement within 180 days after a notice between
        the parties under subsection 6.1.1, then Immunodex shall have the right
        to bring and control suit to end and/or seek damages for the
        infringement.

        6.2.3 Recovery. Any recovery, awarded either Party or Parties in
        connection with an action pursuant to subsection 6.1.2 shall be
        distributed as follows: (i) first, to [CONFIDENTIAL TREATMENT REQUESTED]
        by the Parties in connection with the claim of infringement, and (ii)
        second, with any additional amounts being allocated to [CONFIDENTIAL
        TREATMENT REQUESTED], but if this is [CONFIDENTIAL TREATMENT REQUESTED],
        then [CONFIDENTIAL TREATMENT REQUESTED] must pay [CONFIDENTIAL TREATMENT
        REQUESTED] an amount equal to the [CONFIDENTIAL TREATMENT REQUESTED]
        hereunder on the sales of product underlying such remaining recovery.

                                       21
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

        6.2.4 Indispensable Party. If either Party reasonably determines that
        the other Party is an indispensable party to any action pursuant to this
        Section 6.2.4 the other Party hereby consents to be joined and shall
        bear its own costs only if that party elects to be represented by
        separate counsel.

        6.2.5 Settlement. Neither Party shall settle any action pursuant to this
        Section 6.2 (excluding 6.2.6) without the other Party's written consent
        (such consent not to be unreasonably withheld, delayed or conditioned),
        unless the settlement is for money damages alone.

        6.2.6 Infringement Outside the Field. To avoid any doubt, Somanta shall
        not have any right to enforce any Licensed Patent(s) against
        infringement that is not within the Field and competitive with the
        Somanta's activities hereunder. This is Immunodex's sole and exclusive
        right as between the Parties.

The Parties' agreements regarding patent infringement suits and sharing of
recoveries are subject to the terms of the written agreements by which Immunodex
derives rights in the Licensed Patents, to the full extent applicable. In
particular, the "remaining recovery" after costs are deducted (under subsection
(c)) shall be net of any amounts that may be due Immunodex's licensors.

6.3     Infringement of third party rights

6.3.1   If any warning letter or other notice of infringement is received by a
        Party, or legal suit or other action is brought against a Party,
        alleging infringement of third party rights in the manufacture, use or
        sale of any Royalty-bearing Product or use of any Patents, that Party
        shall promptly provide full details to the other Party, and the Parties
        shall discuss the best way to respond.

6.3.2   Somanta shall have the right but not the obligation to defend such suit
        to the extent that it relates to the Field, and shall have the right to
        settle with such third party, provided that if any action or proposed
        settlement involves the making of any statement, express or implied,
        concerning the validity of any Patent, the consent of Immunodex must be
        obtained before taking such action or making such settlement.
        Furthermore, this Section 6.3.2 shall in no way alter or limit Somanta's
        responsibilities under Article 7.

7.      Warranties and liability; Indemnification

7.1     Immunodex warrants, represents and undertakes as follows:-

        (a)     For avoidance of doubt, Immunodex will transfer and/or disclose
                to Somanta all Know-how (by definition Controlled by Immunodex
                as of the Commencement Date, including, without limitation, all
                manufacturing information, SOP's, assays and protocols in
                Immunodex's Control, and Immunodex will use its commercially

                                       22
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                reasonable efforts (it being understood that Immunodex shall not
                be required to make any payment to any third party in connection
                with this Section 7.1) to obtain from Goodwin Biotechnology, New
                York University and Anmed/Biosafe any and all additional
                information, including, without limitation, manufacturing
                information, SOP's, assays or protocols, in each case that are
                necessary or useful for the exploitation of the Licensed Patents
                and Know-how and have been developed by these entities in the
                course of performing work for CRICC and/or Immunodex;

        (b)     it has the legal capacity and authority to enter into this
                Agreement and perform its obligations under this Agreement and,
                without prejudice to the generality of the foregoing, is
                entitled to sub-license the BrE-3 Patents and Mc-3 Patents and
                sub-license the Know-how to Somanta as provided for in this
                Agreement subject to United States Government rights conferred
                by its participation in the BrE3 Patents: [CONFIDENTIAL
                TREATMENT REQUESTED].

        (c)     it has not done, and will not do nor agree to do during the
                continuation of this Agreement, any of the following things in
                the Field, if to do so would be inconsistent with the exercise
                by Somanta of the rights granted to it under this Agreement,
                namely:

                (i)     grant or agree to grant any right, title or interest in
                        the BrE-3 Patents or Mc3 Patents or the Know-how or any
                        improvements thereto that are included within the
                        Licensed Patents; or
                (ii)    assign, mortgage, charge or otherwise transfer any of
                        the BrE-3 Patents or Mc3 Patents or Know-how or (subject
                        to clause 9.3 below) any of its rights or obligations
                        under this Agreement.
                (iii)   grant or agree to grant any right, title or interest in
                        any Patent or know-how covering or claiming the
                        Lactadherin technology for use in the Field.

7.2     Somanta Representations and Warranties.

Somanta represents and warrants to Immunodex that Somanta has the legal capacity
and authority to enter into this Agreement and perform its obligations under
this Agreement; that this Agreement represents is the legally binding obligation
of Somanta; and that this Agreement has been authorized by all requisite
corporate action within Somanta.

7.3     No other warranties

7.3.1 Each of Somanta and Immunodex acknowledges that, in entering into this
Agreement, it does not do so in reliance on any representation, warranty or
other provision except as expressly provided in this Agreement, and any
conditions, warranties or other terms implied by statute or common law are
excluded from this Agreement to the fullest extent permitted by law. EXCEPT AS
EXPRESSLY SET FORTH IN THIS AGREEMENT, THE PARTIES MAKE NO, AND EXPRESSLY
DISCLAIM ALL, REPRESENTATIONS OR WARRANTIES OF ANY KIND WHATSOEVER, INCLUDING,
WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, TITLE, FITNESS FOR
A PARTICULAR PURPOSE OR NON-INFRINGEMENT.

                                       23
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

7.3.2 Without limiting the scope of Clause 7.3.1, Immunodex does not give any
warranty (and hereby expressly disclaims), representation or undertaking:

        (a)     as to the efficacy or usefulness of the Licensed Patents or
                Know-how; or

        (b)     that any of the Licensed Patents is or will be valid or
                subsisting or (in the case of an application) will proceed to
                grant; or

        (c)     that the use of any of the Licensed Patents or Know-how, the
                manufacture, sale or use of the Royalty-bearing Products or the
                exercise of any of the rights granted under this Agreement will
                not infringe any other intellectual property or other rights of
                any other person; or

        (d)     that the subject matter of the Licensed Patents or Know-how or
                any other information communicated by Immunodex to Somanta under
                or in connection with this Agreement will produce
                Royalty-bearing Products of satisfactory quality or fit for the
                purpose for which Somanta intended; or

        (e)     as imposing any obligation on Immunodex to bring or prosecute
                actions or proceedings against third parties for infringement or
                to defend any action or proceedings for revocation of any of the
                Licensed Patents; or

        (f)     as imposing any liability on Immunodex in the event that any
                third party supplies Royalty-bearing Products to customers
                located in the Territory.

7.4     Liability. EXCEPT WITH RESPECT TO A BREACH OF CONFIDENTIALITY AND/OR
        NON-USE OBLIGATIONS HEREUNDER OR TO THE EXTENT SOMANTA MAY BE REQUIRED
        TO INDEMNIFY IMMUNODEX INDEMNITEES UNDER SECTION 7.4 (INDEMNIFICATION),
        NO PARTY SHALL BE LIABLE TO ANY OTHER PARTY TO THIS AGREEMENT IN
        CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR
        ANY LOSS, DAMAGE, COSTS OR EXPENSES OF ANY NATURE WHATSOEVER INCURRED OR
        SUFFERED BY THAT OTHER PARTY OR ITS AFFILIATES OF AN INDIRECT OR
        CONSEQUENTIAL NATURE INCLUDING WITHOUT LIMITATION ANY ECONOMIC LOSS OR
        OTHER LOSS OF TURNOVER, PROFITS, BUSINESS OR GOODWILL.

7.5     Indemnification. Somanta shall indemnify, defend and hold harmless
        Immunodex, CRICC and their respective members of their boards of
        directors and trustees, officers, employees, agents and consultants
        (each, an "Immunodex Indemnitee") from and against any and all damages,
        losses, liabilities, costs and expenses (including, without limitation,
        attorneys fees) ("Losses") third-party claims (each, a "Claim") arising
        out of or relating to: (1) Somanta's (and its Affiliates' and
        sublicensees') research, development, testing, manufacture, use, sale,
        offer for sale, importation, exportation, storage and distribution of
        Royalty-bearing Products (including, without limitation, products
        liability and intellectual property claims),(2) Somanta's use of
        materials included within the Know-how (including, without limitation,

                                       24
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

        the cell lines transferred pursuant to Section 2.3); (3) Somanta's
        finding that Immunodex is an indispensable party and requiring Immunodex
        to participate in an infringement suit under Section 6.1.1; and (4) the
        conduct of the Ongoing Clinical Trial. Such indemnification shall not
        apply to the portion of any such Losses to the extent such Losses result
        solely from (a) Immunodex's material breach of any of its
        representations and warranties granted hereunder, or (b) the gross
        negligence or intentional misconduct of any Immunodex Indemnitee
        (including without limitation by material failure on their parts to
        follow the then-current protocol for the Ongoing Clinical Trial under
        the written agreement between the parties regarding the conduct for such
        trial being entered into contemporaneously with this Agreement). To the
        extent Somanta provides indemnification relating to (4) hereunder, it
        shall not be required to Indemnify for the same Losses under such
        clinical trial agreement.

8.      Duration and Termination

8.1.    Commencement. This Agreement shall come into full effect on the first
        date set forth on the first page of this Agreement (the "Commencement
        Date"); provided, however, that the sublicenses granted hereunder shall
        come into effect on the date on which Somanta makes the payments set
        forth in Sections 4.1(a) and (c).

8.2     Termination by expiry. Unless terminated earlier in accordance with this
        Clause 8 (Duration and Termination), this Agreement and the sub-licenses
        granted hereunder shall continue in force as follows:

        (i) With respect to the BrE-3 Patents and BrE-3-based Royalty-bearing
        Products, they shall remain in force on a country-by-country and
        product-by-product basis, until the date on which all the BrE-3 Patents
        have expired or been revoked without a right of further appeal, or if
        later when the last obligation to pay royalties on Net Sales Revenue of
        such BrE-3-based Royalty-bearing Product in such country have expired.
        On such latter of the two (2) dates this Agreement and the licenses
        granted hereunder shall terminate automatically by expiry with respect
        to the BrE-3 Patents and such BrE-3-based Royalty-bearing Product in
        such country.

        (ii) With respect to the Mc-3 Patents and Mc-3-based Royalty-bearing
        Products, they shall remain in force on a country-by-country and
        product-by-product basis, until the date on which all the Mc-3 Patents
        have expired or been revoked without a right of further appeal, or if
        later when the last obligation to pay royalties on Net Sales Revenue of
        such Mc-3-based Royalty-bearing Product in such country have expired. On
        such latter of the two (2) dates this Agreement and the licenses granted
        hereunder shall terminate automatically by expiry with respect to the
        Mc-3 Patents and such Mc-3-based Royalty-bearing Product in such
        country.

8.3     Early termination

8.3.1.  By Somanta. Somanta may terminate this Agreement at any time on 90 days
        notice in writing to Immunodex with respect to: (1) this Agreement in
        its entirety, (2) with respect to all BrE-3 Patents and all BrE-3-based

                                       25
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

        Royalty-bearing Products, or (3) with respect to all Mc-3 Patents and
        all Mc-3-based Royalty-bearing Products.

8.3.2.  By either Party for material breach. Without prejudice to any other
        right or remedy, either Party may terminate this Agreement at any time
        by notice in writing to the other Party ("Other Party"), such notice to
        take effect as specified in the notice:

        (a)     if the Other Party is in breach of this Agreement and, in the
                case of a breach capable of remedy within 90 days, the breach is
                not remedied within 90 days of the Other Party receiving notice
                specifying the breach and requiring its remedy (provided that
                the notice and cure period shall be only 30 days for payment
                failures, in accordance with Section 8.3.4; or

        (b)     if the Other Party becomes insolvent, or if an order is made or
                a resolution is passed for the winding up of the Other Party
                (other than voluntarily for the purpose of solvent amalgamation
                or reconstruction), or if an administrator, administrative
                receiver or receiver is appointed in respect of the whole or any
                part of the Other Party's assets or business, or if the Other
                Party makes any composition with its creditors or takes or
                suffers any similar or analogous action in consequence of debt.

8.3.3.  By Immunodex for Licensed Patent Challenge. Immunodex may forthwith
        terminate this Agreement by giving written notice to Somanta if Somanta
        or its Affiliate or licensee or sub-licensee commences legal
        proceedings, or assists any third party to commence legal proceedings,
        to challenge the validity of any of the Licensed Patents.

8.3.4.  Payment Failures. Any failure by Somanta to make payments to Immunodex
        by their respective due dates is a material breach of this Agreement.
        Somanta shall have 30 days to cure its breach by submitting the payment
        due to Immunodex. If the payment due is not made by Somanta within the
        30 day period, this Agreement shall terminate on the expiration of such
        notice period and all rights, without exception, will revert to
        Immunodex. During the delinquent period, Immunodex may charge interest
        on any outstanding amount on a daily basis at a rate equivalent to
        [CONFIDENTIAL TREATMENT REQUESTED] above the prime rate of lending
        published by the U.S. Federal Reserve from time to time (or the maximum
        amount permitted by law, whichever is less).

8.4     Consequences of termination

8.4.1   Upon termination of this Agreement by expiry under clause 8.2 above,
        Somanta shall have the non-exclusive right to use the Know-how to make,
        have made, use, sell, offer to sell and import those Royalty-bearing
        Products in those countries in each case with respect to which this
        Agreement has expired, and may negotiate with Immunodex to seek to reach
        terms upon which it may license such Know-how on an exclusive basis (but
        solely if Immunodex is willing to negotiate the terms of such exclusive
        rights, recognizing its affiliation with a not-for-profit research
        institute and that it may reasonably conclude that it is not willing to
        grant exclusive rights to such Know-how after expiry of this Agreement).

                                       26
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

8.4.2   Upon termination of this Agreement for any reason otherwise than in
        accordance with Clause 8.2 (expiration):

        (a)     Somanta and its licensee or sublicensees shall be entitled to
                sell, use or otherwise dispose of any unsold or unused stocks of
                the Royalty-bearing Products, subject to the payment of
                royalties on such Royalty-bearing Products;

        (b)     subject to paragraph (a) above, Somanta shall no longer be
                entitled as licensee to use or otherwise exploit in any way,
                either directly or indirectly, the BrE-3 Patents or the Mc3
                Patents, in so far and for as long as any of the same remain in
                force, or the Know-how;

        (c)     any sublicense granted by Somanta pursuant to Section 2.2 hereof
                may, at the option of the sub-licensee, be converted into a
                sub-license directly with Immunodex upon the same terms as set
                forth in such sublicense agreement; provided that this is only
                available if the termination was for a material breach that is
                capable of cure, and such sublicensee agrees to make payments
                and reports directly to Immunodex and to remedy of any breach by
                Somanta of this Agreement as promptly as is reasonably
                practicable (with respect to payment breaches, within 30 days);

        (d)     the provisions of clauses 4 (in respect of events occurring and
                sales made prior to termination) and 3.4, 3.5, 7, 8 and 9 shall
                survive termination; and

        (e)     subject to and except as provided in this Clause 8.3.2 and 8.3.3
                and 8.3.4, and except in respect of any accrued rights, neither
                party shall be under any further obligation to the other.

        (f)     If this Agreement (as to BrE-3, Mc-3, or both) is terminated for
                a reason other than an adverse event (within the meaning of
                applicable FDA regulations and related laws) or FDA action, in
                either case precluding further clinical testing of BrE-3 or Mc-3
                (or if this Agreement is terminated as to both of them, both),
                then to the extent not already paid to Immunodex (or CRICC under
                the clinical trial agreement between Somanta and CRICC entered
                into contemporaneously with this Agreement), Somanta agrees to
                pay to Immunodex independent of any other prior consideration or
                stipulation contained in this Agreement the sum [CONFIDENTIAL
                TREATMENT REQUESTED] for each patient included in the Ongoing
                Clinical Trial for whom Somanta receives a completed case
                reporting form during the [CONFIDENTIAL TREATMENT REQUESTED]
                period following the Effective Date, for up to a maximum of
                [CONFIDENTIAL TREATMENT REQUESTED]patients (i.e., a maximum of
                [CONFIDENTIAL TREATMENT REQUESTED].

                                       27
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

8.4.3   Upon termination of this Agreement for any reason (other than
        expiration) and at Immunodex's request, Somanta shall:

        (a)     transfer to Immunodex exclusively all clinical and other data
                relating to the development of Royalty-bearing Products;

        (b)     within thirty (30) days after the date of termination of this
                Agreement, transfer to Immunodex, or, if, as and to the extent
                directed by Immunodex, destroy, all quantities of cell lines
                transferred to Somanta hereunder (including, without limitation
                all progeny of the cells themselves physically transferred to
                Somanta hereunder); all cell banks and any other samples of the
                hybridoma kept in vitro or frozen, or if this Agreement is
                terminated with respect to only the BrE-3 Patents or the Mc-3
                Patents, as the case may be, then only those that relate to the
                terminated portfolio of Licensed Patents (i.e., that relate to
                BrE-3 or Mc-3, respectively); and in either case within thirty
                (30) days of termination of the Agreement, an officer of Somanta
                shall certify in writing on Somanta letterhead Somanta's
                compliance with this Section (such certification to speak
                specifically to each place and each person where cells required
                to be returned or destroyed were stored or into whose physical
                possession they came, and indicate the disposition of the cells
                held at such place or by such person);

        (c)     have any product licenses, pricing approvals and other permits
                and applications transferred into the name of Immunodex or its
                nominee;

        (d)     transfer all rights granted to Somanta under this agreement to
                Immunodex, including without limitation any rights in the
                materials set forth in subsection (b) above and any antibody
                produced by the cell lines then in Somanta's possession;

        (e)     grant Immunodex an exclusive, worldwide license, with the rights
                to grant license or sub-licenses, under any improvements and
                other intellectual property owned or controlled by Somanta
                relating to the Royalty-bearing Products; and

        (f)     grant Immunodex or its nominee the right to continue to use any
                product name that had been applied to the Royalty-bearing
                Products prior to termination of this Agreement.

8.4.4.  If the Parties are unable to agree the terms of a written agreement to
        evidence, record or effect any of Immunodex's rights or any of the
        transfers to Immunodex (should any further written document be
        reasonably required, for example any reasonably required assignment or
        letter of transfer) as described in Clause 8.4.3 within 90 days of
        Immunodex requesting the negotiation of such an agreement, Immunodex may
        refer the terms for settlement by an independent arbitration expert who

                                       28
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

        shall be appointed in accordance with the provisions of Schedule 2 and
        whose decision shall be final and binding on the Parties. The Parties
        shall promptly execute an agreement on the terms agreed between them or
        settled by the expert.

8.4.5.  Nothing in this Agreement shall prevent Immunodex from seeking
        injunctive relief in the case of material breach of this Agreement.

9.      General

9.1.    Force majeure. Neither Party shall have any liability or be deemed to be
        in breach of this Agreement for any delays or failures in performance of
        this Agreement enduring no more than 12 months, which result from
        circumstances beyond the reasonable control of that Party, such as
        earthquake, flood, fire, other natural disaster, and acts of God, war
        and terrorism and including without limitation labour disputes involving
        that Party. The Party affected by such circumstances shall promptly
        notify the other Party in writing when such circumstances cause a delay
        or failure in performance and when they cease to do so.

9.2.    Amendment. This Agreement may only be amended in writing signed by duly
        authorised representatives of Immunodex and Somanta.

9.3.    License and third party rights.

9.3.1.  Except as provided in clause 9.3.2 or 9.3.3, neither Party may assign or
        transfer any or all of its rights and obligations hereunder.

9.3.2.  Neither Party may assign its rights and obligations under this Agreement
        to any entity without the prior written consent of the other Party;
        provided, however, that either Party may assign its rights and
        obligations to any entity succeeding to all or substantially all of such
        Party's business or assets whether by merger or a transaction of another
        form without the written consent of the other Party; provided, further,
        however, that (a) the assignee undertakes to the non-assigning Party to
        be bound by and perform the obligations of the assignor under this
        Agreement, and (b) if Somanta is the assigning Party and the assignment
        is made prior to the Funding (and to avoid any doubt, if committed to
        prior to the Funding, only actually occurs after the Funding), then
        because the licenses granted hereunder will be transferred by the
        assignment and Somanta's other assets prior to the Funding are not
        considered to provide reasonable assurance that assignment will not be a
        mechanism to evade the Parties' agreement as set forth herein regarding
        sublicenses, Immunodex's approval is required on the same conditions as
        for sublicensing set forth in Section 2.2. Notwithstanding anything to
        the contrary in this Agreement (but subject of course to proviso (a)
        above regarding the assignee's undertakings and the requirements of the
        next paragraph regarding an informational meeting with the assignee
        after assignment), this Agreement and all the rights and obligations
        under this Agreement may be assigned without the prior written consent
        of Immunodex or the approval of Immunodex or its licensors as required
        by Section 2.2 hereof to: (i) Bridge Oncology Products, Inc. (or Somanta
        Incorporated if Bridge Oncology Products, Inc. so changes its name), a

                                       29
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

        Delaware corporation, (ii) a to be identified entity that is subject to
        the reporting requirements of the Securities and Exchange of 1934, as
        amended (the "Public Shell") in connection with a reverse merger with
        such Public Shell, provided that the shareholders of Somanta
        Incorporated hold a majority of the outstanding voting securities of
        such Public Shell immediately after such assignment, and (iii) to any
        entity succeeding to all or substantially all of the assigning party's
        business or assets whether by merger or a transaction of another form
        after the Funding.

        If Somanta assigns this Agreement, Somanta will use commercially
        reasonable efforts to include as a condition of such assignment the
        obligation that the assignee shall meet with Immunodex to review
        development (and if applicable at that stage, commercialization) plans
        for the Royalty-bearing Products, within 6 months after the assignment.
        This meeting is for communication and information sharing purposes only
        and does not impose any additional diligence requirements on the
        assignee.

9.3.3.  In connection with monetizing its royalty stream under this Agreement,
        Immunodex may assign this Agreement to an entity purchasing from
        Immunodex the right to receive payments from Somanta hereunder.

9.4.    Waiver. No failure or delay on the part of either Party to exercise any
        right or remedy under this Agreement shall be construed or operate as a
        waiver thereof, nor shall any single or partial exercise of any right or
        remedy preclude the further exercise of such right or remedy.

9.5.    Invalid clauses. If any provision or part of this Agreement is held to
        be invalid, illegal or unenforceable, amendments to this Agreement may
        be made by the addition or deletion of wording as appropriate to remove
        the invalid, illegal or unenforceable part or provision but otherwise
        retain the provision and the other provisions of this Agreement to the
        maximum extent permissible under applicable law.

9.6.    No Agency, Joint Venture or Partnership. Neither Party shall act or
        describe itself as the agent of the other, nor shall it make or
        represent that it has authority to make any commitments on the other's
        behalf. This Agreement does not create any joint venture or partnership
        between the Parties and they are operating as independent contractors
        with respect to one another.

9.7.    Interpretation. In this Agreement:

        (a)     the headings are used for convenience only and shall not affect
                its interpretation;

        (b)     references to persons shall include incorporated and
                unincorporated persons; references to the singular include the
                plural and vice versa; and references to the masculine include
                the feminine;

        (c)     references to Clauses and Schedules mean clauses of, and
                schedules to, this Agreement; and

                                       30
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

9.8     Notices

i.      Any notice to be given under this Agreement shall be in writing and
        shall be sent by first class mail or air mail, or by fax (confirmed by
        first class mail or air mail) to the address of the relevant Party set
        out at the head of this Agreement, or to the relevant fax number set out
        below, or such other address or fax number as that Party may from time
        to time notify to the other Party in accordance with this Clause 9.8.
        The fax numbers of the Parties are as follows: Immunodex- (707)
        441-1822; Somanta 940-706-3698.

ii.     Notices sent as above shall be deemed to have been received three
        working days after the day of posting (in the case of inland first class
        mail), or seven working days after the date of posting (in the case of
        air mail), or on the next working day after transmission (in the case of
        fax messages, but only if a transmission report is generated by the
        sender's fax machine recording a message from the recipient's fax
        machine, confirming that the fax was sent to the number indicated above
        and confirming that all pages were successfully transmitted).

b.      Law and Jurisdiction. The validity, construction and performance of this
        Agreement shall be governed solely and exclusively by the laws of the
        State of California of the United States of America and shall be subject
        to exclusive jurisdiction of the courts located in the State of
        California within the United States of America. Each party hereby
        consents to the jurisdiction (including, without limitation, personal
        jurisdiction) and venue of the courts of such State of California, and
        waives any and all defenses it may have to the jurisdiction and venue of
        such courts, including, without limitation, the defense of forum non
        conveniens.

c.      Further action. Each Party agrees to execute, acknowledge and deliver
        such further instruments, and do all further similar acts, as may be
        necessary or appropriate to carry out the purposes and intent of this
        Agreement.

d.      Announcements. Neither Party shall make any press or other public
        announcement concerning any aspect of this Agreement, or make any use of
        the name of the other Party in connection with or in consequence of this
        Agreement, without the prior written consent of the other Party, except
        in connection with any fundraising by Somanta or as required by
        applicable law, unless required to make such announcement by applicable
        law, including, without limitation, the rules and regulations
        promulgated by the Securities and Exchange Commission of the United
        States of America. If Somanta is required to publicly file a copy of
        this Agreement, then it shall seek confidential treatment of the terms
        of this Agreement to the extent reasonably requested by Immunodex and
        reasonably available under applicable law (as advised by outside
        counsel). Somanta shall afford Immunodex no less than one (1) working
        week (excluding US holidays) to comment on any proposed redactions.

                                       31
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

e.      Entire agreement. This Agreement, including its Schedules, constitutes
        the entire Agreement between Somanta and Immunodex with respect to the
        subject matter hereof and supersedes all prior or contemporaneous
        agreements between Somanta and Immunodex related to the subject matter
        hereof, including, without limitation, that certain Patent and Know-how
        License Option Agreement dated March 1, 2002 as amended by that certain
        Amendment No. 1 to Patent and Know-how License Option Agreement dated
        January 2, 2003, that certain Amendment No. 2 to Patent and Know-how
        License Option Agreement dated October 14, 2003 and that certain
        Amendment No. 3 to Patent and Know-how License Option Agreement dated
        October 29, 2004. The Parties hereby acknowledge and agree that the
        Patent and Know-how License Option Agreement dated March 1, 2002, as
        amended to date is hereby terminated and shall no longer have any
        further force or effect.

9.9     The terms of this agreement are confidential and are not to be disclosed
        to any third party by Immunodex, CRICC or Somanta without prior written
        approval of the other parties, subject to subsection 9.8(d) above.

                                       32
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

AGREED by the parties through their authorised signatories:-

For and on behalf of                      For and on behalf of
IMMUNODEX, Inc.                           SOMANTA LIMITED

/s/ ROBERTO L. CERIANI                    /s/ TERRENCE J. BRUGGEMAN
----------------------------------        ----------------------------------
signed                                    signed

Roberto L. Ceriani                        Terrence J. Bruggeman
----------------------------------        ----------------------------------
print name                                print name

President                                 Chairman
----------------------------------        ----------------------------------
title                                     title

8/18/05                                   8/15/05
----------------------------------        ----------------------------------
date                                      date

                                       33
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                   Schedule 1

                                   The Patents

Part A - BrE-3 Patents

     1.  [CONFIDENTIAL TREATMENT REQUESTED]
     2.  [CONFIDENTIAL TREATMENT REQUESTED]
     3.  [CONFIDENTIAL TREATMENT REQUESTED]

Part B - Mc-3 Patent

     4.  [CONFIDENTIAL TREATMENT REQUESTED]

                                       34
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                   Schedule 2

Appointment of expert

1.    Pursuant to Clause 8.4.4, Immunodex, may serve notice on Somanta
      ("Referral Notice") that it wishes to refer to an expert (the "Expert")
      the questions set out in Clause 8.4.4.

2.    The parties shall agree the identity of a single independent, impartial
      expert to determine such questions. In the absence of such agreement
      within 30 days of the Referral Notice, the questions shall be referred to
      an expert appointed by the California Bar Association.

3.    60 days after the giving of a Referral Notice, both parties shall exchange
      simultaneously statements of case in no more than 10,000 words, in total,
      and each side shall simultaneously send a copy of its statement of case to
      the Expert.

4.    Each party may, within 30 days of the date of exchange of statement of
      case pursuant to paragraph 3 above, serve a reply to the other side's
      statement of case of not more than 10,000 words. A copy of any such reply
      shall be simultaneously sent to the Expert.

5.    The Expert shall make his decision on the said questions on the basis of
      written statements and supporting documentation only and there shall be no
      oral hearing. The Expert shall issue his decision in writing within 30
      days of the date of service of the last reply pursuant to paragraph 4
      above or, in the absence of receipt of any replies, within 60 days of the
      date of exchange pursuant to paragraph 3 above.

6.    The Expert's decision shall be final and binding on the parties.

7.    The Expert's charges shall be borne equally by the parties.

                                       35

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}]]